NCT03681093 - Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

May 29, 2020

Study Completion Date

June 10, 2020

Conditions

Nasal Polyps

Interventions

DRUG

Fevipiprant 150 mg

Fevipiprant (QAW039) 150 mg once daily administered orally as tablet

DRUG

Fevipiprant 450 mg

Fevipiprant (QAW039) 450 mg once daily administered orally as tablet

DRUG

Placebo

Placebo once daily administered orally as tablet

Trial Locations (25)

1200

Novartis Investigative Site, Brussels

4000

Novartis Investigative Site, San Miguel de Tucumán

5100

Novartis Investigative Site, Erpent

5500

Novartis Investigative Site, Mendoza

20089

Novartis Investigative Site, Rozzano

27259

Novartis Investigative Site, Kladno

56124

Novartis Investigative Site, Pisa

60596

Novartis Investigative Site, Frankfurt

92618

Novartis Investigative Site, Irvine

C1414AIF

Novartis Investigative Site, CABA

C1425BEN

Novartis Investigative Site, CABA

C1426ABP

Novartis Investigative Site, CABA

B1602DQD

Novartis Investigative Site, Florida

S2000DBS

Novartis Investigative Site, Rosario

C1125ABE

Novartis Investigative Site, Buenos Aires

K1G 6C6

Novartis Investigative Site, Ottawa

G1V 4W2

Novartis Investigative Site, Québec

779 00

Novartis Investigative Site, Olomouc

568 25

Novartis Investigative Site, Svitavy

01307

Novartis Investigative Site, Dresden

00168

Novartis Investigative Site, Roma

Unknown

Novartis Investigative Site, Amsterdam

7511 JH

Novartis Investigative Site, Enschede

47 100

Novartis Investigative Site, Strzelce Opolskie

47-120

Novartis Investigative Site, Zawadzkie